503 related articles for article (PubMed ID: 27639753)
1. A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I.
Roth EM; Moriarty PM; Bergeron J; Langslet G; Manvelian G; Zhao J; Baccara-Dinet MT; Rader DJ;
Atherosclerosis; 2016 Nov; 254():254-262. PubMed ID: 27639753
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
Stroes E; Guyton JR; Lepor N; Civeira F; Gaudet D; Watts GF; Baccara-Dinet MT; Lecorps G; Manvelian G; Farnier M;
J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27625344
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON.
Teramoto T; Kiyosue A; Ishigaki Y; Harada-Shiba M; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
J Cardiol; 2019 Mar; 73(3):218-227. PubMed ID: 30509509
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
Teramoto T; Kondo A; Kiyosue A; Harada-Shiba M; Ishigaki Y; Tobita K; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
Lipids Health Dis; 2017 Jun; 16(1):121. PubMed ID: 28623954
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial.
Roth EM; Kastelein JJP; Cannon CP; Farnier M; McKenney JM; DiCioccio AT; Brunet A; Manvelian G; Sasiela WJ; Baccara-Dinet MT; Zhao J; Robinson JG
J Clin Lipidol; 2020; 14(5):707-719. PubMed ID: 32928709
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
Kereiakes DJ; Robinson JG; Cannon CP; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM
Am Heart J; 2015 Jun; 169(6):906-915.e13. PubMed ID: 26027630
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin.
Müller-Wieland D; Rader DJ; Moriarty PM; Bergeron J; Langslet G; Ray KK; Manvelian G; Thompson D; Bujas-Bobanovic M; Roth EM
J Clin Endocrinol Metab; 2019 Nov; 104(11):5253-5262. PubMed ID: 31166599
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.
Colhoun HM; Robinson JG; Farnier M; Cariou B; Blom D; Kereiakes DJ; Lorenzato C; Pordy R; Chaudhari U
BMC Cardiovasc Disord; 2014 Sep; 14():121. PubMed ID: 25240705
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.
Cannon CP; Cariou B; Blom D; McKenney JM; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM;
Eur Heart J; 2015 May; 36(19):1186-94. PubMed ID: 25687353
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
Farnier M; Jones P; Severance R; Averna M; Steinhagen-Thiessen E; Colhoun HM; Du Y; Hanotin C; Donahue S
Atherosclerosis; 2016 Jan; 244():138-46. PubMed ID: 26638010
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.
Moriarty PM; Thompson PD; Cannon CP; Guyton JR; Bergeron J; Zieve FJ; Bruckert E; Jacobson TA; Kopecky SL; Baccara-Dinet MT; Du Y; Pordy R; Gipe DA;
J Clin Lipidol; 2015; 9(6):758-769. PubMed ID: 26687696
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
Kastelein JJ; Hovingh GK; Langslet G; Baccara-Dinet MT; Gipe DA; Chaudhari U; Zhao J; Minini P; Farnier M
J Clin Lipidol; 2017; 11(1):195-203.e4. PubMed ID: 28391886
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E
Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825
[TBL] [Abstract][Full Text] [Related]
15. Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
Santos RD; Wiegman A; Caprio S; Cariou B; Averna M; Poulouin Y; Scemama M; Manvelian G; Garon G; Daniels S
JAMA Pediatr; 2024 Mar; 178(3):283-293. PubMed ID: 38315470
[TBL] [Abstract][Full Text] [Related]
16. Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II.
Leiter LA; Zamorano JL; Bujas-Bobanovic M; Louie MJ; Lecorps G; Cannon CP; Handelsman Y
Diabetes Obes Metab; 2017 Jul; 19(7):989-996. PubMed ID: 28206704
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Robinson JG; Farnier M; Krempf M; Bergeron J; Luc G; Averna M; Stroes ES; Langslet G; Raal FJ; El Shahawy M; Koren MJ; Lepor NE; Lorenzato C; Pordy R; Chaudhari U; Kastelein JJ;
N Engl J Med; 2015 Apr; 372(16):1489-99. PubMed ID: 25773378
[TBL] [Abstract][Full Text] [Related]
18. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
[TBL] [Abstract][Full Text] [Related]
19. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study.
Nam CW; Kim DS; Li J; Baccara-Dinet MT; Li I; Kim JH; Kim CJ
Korean J Intern Med; 2019 Nov; 34(6):1252-1262. PubMed ID: 30257549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
